Ratings Formycon AG Börse Stuttgart

Equities

FYB

DE000A1EWVY8

Real-time Estimate Tradegate Other stock markets 08:43:43 2024-06-24 EDT			5-day change	1st Jan Change
53.3 ^EUR	+2.70%		+12.10%	-6.65%

06-18	Borse Frankfurt-News: Many winners and many losers (second-line stocks)	DP
06-13	Formycon Starts Clinical Trials of Keytruda Biosimilar Candidate for Skin Cancer Therapy	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is in a robust financial situation considering its net cash and margin position.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
FORMYCON AG	-6.65%	987M	-
MODERNA, INC.	+34.14%	51.12B	B-
IQVIA HOLDINGS INC.	-6.54%	39.4B	B
LONZA GROUP AG	+36.10%	38.48B	A
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B	B-
CELLTRION, INC.	-12.11%	26.22B	C
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B	B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B	B+
MEDPACE HOLDINGS, INC.	+31.81%	12.49B	C+
BIO-TECHNE CORPORATION	-4.54%	11.61B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes